ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AMYT Amryt Pharma Plc

143.00
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 143.00 151.00 170.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Amryt Pharma Share Discussion Threads

Showing 5201 to 5224 of 7375 messages
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older
DateSubjectAuthorDiscuss
22/10/2019
10:33
Thanks BS

I see that Amryt are at both the Shares Mag and Proactive investor meetings this week (tomorrow and Thursday), so I will probably go along to one or both

On the subject of CVRs, I hold a few Amryt shares on a certificate and a few in the ISA, I have now received 3 additional certificates for the CVRs, but there is nothing showing in my ISA account or in notifications to tell me that the CVRs have been allocated and need to be transferred out.

Lastly, I found this short video on Rhys, a 14 year old boy with very severe EB on BBC iplayer. It was first shown on Sept 23rd, but I am not sure whether it has been posted here before:

timbo003
21/10/2019
18:33
Link below to latest presentation from Kieran Rooney
bermudashorts
21/10/2019
10:43
From the lse bb:

Bronxville
Posts: 1,265
Price: 116.50
No Opinion
AMRYT'S baby
Today 08:42
Irish scientists announce breakthrough on genetic skin disease
21/10/2019 - 06:36

By Press Association

Irish researchers have announced a breakthrough in the search for a cure for a painful skin disease.

Epidermolysis bullosa (EB) is a genetic condition in which sufferers lack a vital protein responsible for binding skin.

This results in painful blisters – both internal and external – from the slightest knock or bump.

The disease affects approximately 300 people in Ireland.

Researchers at University College Dublin (UCD) say they have now produced a solution that uses gene therapy to repair bad cells.

The best part of this therapy is that it would not involve painful skin grafting procedures or risks associated with viral treatments in delivering functioning genes to the skin

The breakthrough has the potential to provide a permanent cure for patients with Recessive Dystrophic EB, one of the most severe sub-types of the disease, for which no treatment currently exists.

The concept has been pioneered by Professor Wenxin Wang, who has been carrying out research into EB for the past 10 years, with assistance from the charity Debra Ireland.

Dr Jonathan O’Keeffe Ahern, one of the leading gene therapy researchers in Professor Wang’s team, said one of the greatest benefits of the solution is that it removes the need for painful surgery.

“The best part of this therapy is that it would not involve painful skin grafting procedures or risks associated with viral treatments in delivering functioning genes to the skin,” he said.

Gene therarpy researchers Dr Irene Lara-Saez and Dr Jonathan O’Keeffe Ahern (Shane O’Neill/PA)

“We call this the Fed Ex of gene editing – we deliver a biological solution using a simple carrier system.

“Rather like using a postcode, we can send in a genetic scissors to cut out the non-functioning part of a gene and then the repaired cells know to fill that space and permanently repair the gene.

“We would not need to even take the patient cells for skin grafting. The gel would be applied, absorbed and go to work.

“We have seen some promising results in the lab. With further research, we could expand this to other EB types and even other genetic conditions.

“We are in the process of forming our own spin-out company to continue to develop this technology and take it to the next step, a clinical trial.”

Debra Ireland head of research Dr Sinead Hickey (centre) with Dr Jonathan O’Keeffe Ahern and Dr Irene Lara-Saez, of the University College Dublin gene therapy research team (Shane O’Neill/PA)

Debra Ireland provides day-to-day help and support for EB patients and their families and also works to find better treatments and possible cures for EB.

This week (October 21-27) is National EB Awareness Week and the charity is asking the public to get involved by wearing a butterfly tattoo to raise awareness for this rare disease and funds for further .

Cionnathagad
Posts: 51
Price: 116.50
No Opinion
RE: AMRYT'S baby
Today 09:49
Sounds good.
Amryt has licensed this therapy as AP103.I just picked up another 4k to have a nice round figure.

Bronxville
Posts: 1,265
Price: 116.50
No Opinion
RE: AMRYT'S baby
Today 10:05
Here's hoping we get fast track approval..
That's my 10k earlier...I've too much tied up in BOI at the moment to buy more...(:

Bronxville
Posts: 1,265
Price: 116.50
No Opinion
RE: AMRYT'S baby
Today 10:22
It sounds to me like this therapy could be used for other skin conditions.. I'm wondering about Melanoma?

Diamondstar might know..

papillon
21/10/2019
08:38
University College Dublin have found a cure for Recessive Dystrophic EB.
Thank God.

Heard it on the radio just now.

It's EB awareness week .

chica1
20/10/2019
17:52
90 days could take us into December, ab321. Obviously Cathal Friel was being more optimistic. Was his optimistic forecast nothing more than just wishful thinking?

4 share trades Wednesday for 45 shares. 4 trades Thursday for 3862 shares. 2 trades Friday for 1888 shares. So just 4795 shares traded over 3 days at a total cost of £6425 and 20p. This for a company with a Mkt Cap of around £180m. The MM's will soon be passing round the hat and the begging bowl! LOL.

papillon
20/10/2019
14:19
Admission doc says within 90 days of deal closing, hopefully sooner rather than later
alphabravo321
18/10/2019
12:02
Well alphabravo, Cathal Friel recently predicted that new AMYT would list on Nasdaq in October. Only 9 trading days left if Friel's prediction is to come true.
papillon
17/10/2019
14:22
Are we expecting much news on the 23rd?
tiananmen
16/10/2019
20:57
I think AIM is the problem, roll on US listing
alphabravo321
16/10/2019
19:59
Just 4 trades today. All sells. All very, very, small. 2 for just 3 shares each both @ 115.07p, 1 for 32 shares and another 1 for 7 shares both @ 115p.

So a grand total of just 45 shares and cash proceeds of a miserable 51 quid and 25p.

Simply AMAZINGLY low turnover for a company with a Mkt Cap of circa 180m. Admittedly there is a relatively small free float percentage, but even so today's volume is pitifully small for a company with a Mkt Cap of circa 180m.

papillon
16/10/2019
12:58
You've sold all your shares then Pap?
tiananmen
16/10/2019
12:14
just 3 trades so far today. All 3 are tiny. 2 sells of 3 shares and 1 sell of 32 shares. TOTAL shares traded just 38 shares!!!!!!!!!!!!!!!!! TOTAL VALUE just 43 QUID plus 20 pence!!!!!!!!!!!!!! ROFLMAO
papillon
15/10/2019
15:43
Some big trades today including a large buy (50k @ 115p). Beginning to look like the share price bottomed last week? Possible. Surely we should be getting the Nasdaq listing news soon? Bring it on!
papillon
11/10/2019
11:24
A return to the early Septembers low of circa 103 seems possible in the short term.
papillon
10/10/2019
22:26
Very Sensible post on the lse by gameangler:

gameangler
Posts: 101
Price: 113.00
No Opinion
RE: Thoughts...
Today 22:33
Novelion could arrange for Amryt Shares to be placed in the market (unless they have a timing constraint), and the proceeds together with the cash passed to their shareholders.
Alternatively there could be, pro rata transfers in specie to Novelion shareholders. The majority of shareholder are funds, so the directors may move with the majority preference. We will have to wait and see.

Not withstanding how they dispose of these shares, I wouldn't follow Amryt share price as a guide to its value at this time. The $60m fundraising shares( without CVRs), were bought by insiders, including Private Equity Funds, at £1.44 a share on 25th Sept. This is an informed valuation of the new Amryt.
Since 20th Sep, Amryt shares have been falling from the high point of £1.41 when CVRs were created. Some shareholders could be liquidating holdings to use the funds elsewhere, but retaining their CVRs.
Expect some volatility until these issues play out and we get a bit more certainty.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

"Since 20th Sep, Amryt shares have been falling from the high point of £1.41 when CVRs were created. Some shareholders could be liquidating holdings to use the funds elsewhere, but retaining their CVRs"

Credit where credit is due. mdalos got it spot on. Hats off to mdalos. He sold his AMYT shares, but has got the CVR's (or so he says). Me? I did the right thing in selling 500 shares, but I should have sold more and I was too quick to buy that 750 shares. I guessed that the share price would fall back (hence the 500 sell, but should have sold more), but have failed to pick the bottom (hence poorly judged 750 buy).

PS gameangler says "I wouldn't follow Amryt share price as a guide to its value at this time. The $60m fundraising shares( without CVRs), were bought by insiders, including Private Equity Funds, at £1.44 a share on 25th Sept. This is an informed valuation of the new Amryt."

A word of caution on that "informed" 144p valuation. After all the 3 funds managed by Neil Woodford must have thought 400p was a fair valuation for KIE because they backed the placing at that price big time. However within months the KIE share price was sub 100p (it's currently around 110p). Funds can and do get it wrong, just like PI's

papillon
10/10/2019
16:38
chica, Bermudashorts provides the link to the "Liquidation Process" quoted in cadburyhill's post. Obviously Bermudashorts and cadburyhill have done their homework on Novelion, AMYT & Aegerion. I, on the other hand, profess ignorance!! I'm just a mug punter checking the AMYT share price daily!!!!!!!!!!!!!!!!
papillon
10/10/2019
16:28
chica. Read cadburyhill's last post timed at 15:40 which was a reply to Bronxville. Here's part of that cadburthill post. Bronxville by the way thanked cadburyhill for their input.

"exactly...so novelion holders wait for the redistribution of the proceeds from the sale of the amyrt stake on the liquidation of novelion. see below. in fact, it may well be simpler than i've thought it was: perhaps the novelion stake is simply an overhang that needs to be cleared asap. but i still suspect that if novelion is or was trading OTC at a worthwhile discount to the proceeds of an amryt's stake's sale and its redistribution to novelion shareholders, then this is a trade that a special sits fund will try and exploit.

"The Liquidation Proposal follows the previously announced completion of the acquisition by Amryt Pharma plc (“Amryt”) of 100% of the outstanding equity interests of Novelion’s former operating subsidiary, Aegerion Pharmaceuticals, Inc. (“AegerionR21;), as contemplated in Aegerion’s First Amended Joint Chapter 11 Plan (the “Aegerion Transaction”). In the Aegerion Transaction, which closed September 24, 2019, reorganized Aegerion became a wholly-owned subsidiary of Amryt and Novelion received American depository receipts representing approximately 14.0 million ordinary shares of Amryt (the “Amryt Equity”) in full satisfaction of Novelion’s claims as creditor under the secured intercompany loan between Aegerion and Novelion."

papillon
10/10/2019
16:24
Think the plan for some time has been for Novelion to be wound up on completion of the sale of Aegerion. Anyway, here is press release from last week:-
bermudashorts
10/10/2019
16:16
You're right chaps, hadn't noticed that in the HL email but it does say they have to be moved out of the ISA within 30 days. It says further information will be provided about how this works but heard nothing yet. I guess they'll just get transferred into a standard share trading account.
webpax
10/10/2019
16:01
Cheers Bermuda, thought I was going nuts for a moment. Good that those in an ISA can be moved. I hold in SIPP and trading account so it didn't come up for me.
waterloo01
10/10/2019
15:55
I was reading on the LSE.
Bronxville says Novelion has been delisted from the Nasdaq on October 8th.
How can arbitrage between the 2 shares happen if that is the case.

chica1
10/10/2019
15:51
webpax, maybe I'm wrong as you seem to have them in an ISA. I was sure I read they couldn't be. Will look but I might be wrong.
waterloo01
10/10/2019
15:49
webpax,

I spoke to HL today, they'll be contacting shareholders within a week or so with arrangements for moving the CVRs out of their ISAs. You also should have received a message from HL outlining the terms of the CVRS and that also confirmed that they can't be held in an ISA.

bermudashorts
10/10/2019
15:42
waterloo0110 Oct '19 - 08:41 - 5039 of 5044
0 0 0
Can't hold them in an ISA. They did make that clear.

Where was this made clear waterloo01?
I've had them credited to my Hargreaves Lansdown ISA, but nothing in my IG ISA yet.

webpax
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older

Your Recent History

Delayed Upgrade Clock